- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05400746
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
December 13, 2022 updated by: University of Oxford
A Phase Ia Study to Assess Safety and Immunogenicity of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in Healthy Adults Living in the UK
This is an open label, single-site, first-in-human, dose-escalation Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs48/45 in Matrix-M adjuvant in healthy adults living in the UK
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Volunteers will be recruited into one of three groups (n=8-10 per group) at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford over approximately 12 months.
All volunteers will receive three dose of Pfs48/45 in 50 µg Matrix-M, administered intramuscularly and given four weeks apart.
Enrolment will be staggered with clinical and safety reviews, follow-up visits and monitoring via a diary card.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Volunteer Recruitment Co-ordinator Volunteer Recruitment Co-ordinator
- Phone Number: 01865 611424
- Email: vaccinetrials@ndm.ox.ac.uk
Study Locations
-
-
-
Oxford, United Kingdom, OX3 7LE
- Recruiting
- CCVTM, University of Oxford
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adult aged 18 to 45 years.
- Able and willing (in the Investigator's opinion) to comply with all study requirements.
- Willing to allow the Investigators to discuss the volunteer's medical history with their GP.
- Volunteers with the potential to become pregnant only: must practice continuous effective contraception for the duration of the study (see section 10.10).
- Agreement to refrain from blood donation for the duration of the study.
- Able and willing to provide written informed consent to participate in the trial
Exclusion Criteria:
- History of clinical malaria (any species).
- Travel to a clearly malaria endemic locality during the study period or within the preceding six months.
- Use of immunoglobulins or blood products (e.g., blood transfusion) in the last three months.
- Receipt of any vaccine in the 30 days preceding enrolment, or planned receipt of any other vaccine within 30 days following each study vaccination, with the exception of COVID-19 vaccines, which should not be received between 14 days before to 7 days after any study vaccination.
- Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.
- Concurrent involvement in another clinical trial or planned involvement during the study period.
- Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data, as assessed by the Investigator.
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Any history of anaphylaxis in reaction to vaccinations.
- Pregnancy, lactation or intention to become pregnant during the study.
- History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
- History of serious psychiatric condition that may affect participation in the study.
- Any other serious chronic illness requiring hospital specialist supervision.
- Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 25 standard UK units every week.
- Suspected or known injecting drug abuse in the 5 years preceding enrolment.
- Hepatitis B surface antigen (HBsAg) detected in serum.
- Seropositive for hepatitis C virus (antibodies to HCV) at screening (unless volunteer has taken part in a prior hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV ribonucleic acid (RNA) PCR at screening for this study).
- Volunteers unable to be closely followed for social, geographic or psychological reasons.
- Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination. In the event of abnormal test results, confirmatory repeat tests will be requested. Procedures for identifying laboratory values meeting exclusion criteria are shown in SOP VC027.
- Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
- Inability of the study team to contact the volunteer's GP to confirm medical history
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 - low dose
8-10 volunteers receiving three doses of 10 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
|
Three doses of Pfs48/45 in Matrix-M at different doses
|
Experimental: Group 2 - standard dose
8-10 volunteers receiving three doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
|
Three doses of Pfs48/45 in Matrix-M at different doses
|
Experimental: Group 3 - fractional dose
8-10 volunteers receiving two doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0 and 28, followed by one dose of 10 µg Pfs48/45 in 50 µg Matrix-M on day 56 via intramuscular injection (IM) in the deltoid region of the arm
|
Three doses of Pfs48/45 in Matrix-M at different doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers by assessing the occurrence of solicited local reactogenicity signs and symptoms for 7 days following each vaccination
Time Frame: 7 days following each vaccination
|
Occurrence of solicited local reactogenicity signs and symptoms for 7 days following each vaccination using e-diaries, clinical review, clinical examination (including observations) and laboratory results
|
7 days following each vaccination
|
To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers by assessing the occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following each vaccination
Time Frame: 7 days following each vaccination
|
Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following each vaccination using e-diaries, clinical review, clinical examination (including observations) and laboratory results
|
7 days following each vaccination
|
To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers by assessing the occurrence of unsolicited adverse events (AEs) for 28 days following the vaccination
Time Frame: 28 days following the vaccination
|
Occurrence of unsolicited adverse events (AEs) for 28 days following the vaccination using e-diaries, clinical review, clinical examination (including observations) and laboratory results
|
28 days following the vaccination
|
To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers. assessed through the number of participants with abnormal laboratory test results
Time Frame: 28 days following vaccination
|
Occurrence of change from baseline laboratory tests
|
28 days following vaccination
|
To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers assessed through the number of participants with serious adverse events
Time Frame: Whole duration of the study (8 months following initial trial vaccination)
|
Occurrence of serious adverse events and will be presented according to local grading scales
|
Whole duration of the study (8 months following initial trial vaccination)
|
To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers.
Time Frame: Whole duration of the study (8 months following initial trial vaccination)
|
Occurrence of AEs of special interest and will be presented according to local grading scales and will be described in detail
|
Whole duration of the study (8 months following initial trial vaccination)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the humoral immunogenicity of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers as assessed by humoral responses to the Pfs48/45 protein
Time Frame: Days 1, 29, 57, 140 and 240
|
Antibody responses to the Pfs48/45 protein will be assessed through total IgG isotypes and avidity
|
Days 1, 29, 57, 140 and 240
|
To assess the cellular immunogenicity of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers as assessed by cellular responses to the Pfs48/45 protein
Time Frame: Days 1, 29, 57, 140 and 240
|
T cell responses to Pfs48/45 will be assessed by ex vivo enzyme-linked immunospot assays (ELISpot)
|
Days 1, 29, 57, 140 and 240
|
To assess ex vivo efficacy of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers using direct membrane feeding assays as assessed by transmission-reducing activity
Time Frame: Days 1, 29, 57, 140 and 240
|
Transmission-reducing activity
|
Days 1, 29, 57, 140 and 240
|
To assess ex vivo efficacy of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers using direct membrane feeding assays as assessed by transmission-blocking activity
Time Frame: Days 1, 29, 57, 140 and 240
|
Transmission-blocking activity
|
Days 1, 29, 57, 140 and 240
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 2, 2022
Primary Completion (Anticipated)
May 30, 2023
Study Completion (Anticipated)
May 30, 2023
Study Registration Dates
First Submitted
May 26, 2022
First Submitted That Met QC Criteria
May 26, 2022
First Posted (Actual)
June 2, 2022
Study Record Updates
Last Update Posted (Estimate)
December 14, 2022
Last Update Submitted That Met QC Criteria
December 13, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAC085
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Pfs48/45 in Matrix-M
-
University of OxfordCompleted
-
University of OxfordIfakara Health InstituteRecruiting
-
University of OxfordBill and Melinda Gates Foundation; University Hospitals Bristol and Weston...RecruitingMalaria,FalciparumUnited Kingdom
-
University of OxfordCompleted
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Institut...CompletedMalaria,FalciparumBurkina Faso
-
University of OxfordRecruitingMalaria,FalciparumBurkina Faso
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Ifakara...Active, not recruitingMalaria,FalciparumTanzania
-
University of OxfordRecruitingInfections | Vector Borne Diseases | Protozoan Infections | Malaria | Malaria,Falciparum | Parasitic DiseaseUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Recruiting
-
University of OxfordMRC/UVRI and LSHTM Uganda Research UnitRecruiting